Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, María Laura Fox, Donal P. McLornan et al.|The Lancet|2023Cited by 181
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Claire Harrison et al.|Leukemia|2022Cited by 63
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Clinical Cancer Research|2022Cited by 41
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Udai Banerji, Ruth Plummer et al.|British Journal of Cancer|2023Cited by 36
Mean plasma SRA737 concentration over time from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert H. Jones, Udai Banerji, Ruth Plummer et al.|Unknown|2023Cited by 2